Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of 6MW3211 in advanced lung cancer after PD-1/PD-L1 inhibitor failure
CTR20221465Phase 2Terminated
- Sponsor
- Maiwei Biotech
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3211 in bronchial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Maiwei Biotech. Started Aug 2022; status: terminated.
02
Drugs
6MW3211
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221465.